Clinical Trial Update: RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating RC48-ADC in combination with bevacizumab for HER2-positive advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN